A toxic organic solvent-free technology for the preparation of PEGylated paclitaxel nanosuspension based on human serum albumin for effective cancer therapy

International Journal of Nanomedicine

Volumn 10, Issue , 2015, Pages 7397-7412

  Yin, Tingjie ^a   Dong, Lihui ^a   Cui, Bei ^a   Wang, Lei ^a   Yin, Lifang ^a   Zhou, Jianping ^a   Huo, Meirong ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

Human serum albumin; Nanosuspension; Paclitaxel; Polyethylene glycol; Solid dispersion technology

Indexed keywords

CREMOPHOR; HUMAN SERUM ALBUMIN; MACROGOL; ORGANIC SOLVENT; PACLITAXEL; ANTINEOPLASTIC AGENT; MACROGOL DERIVATIVE; MICELLE; SUSPENSION;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CANCER THERAPY; CIRCULATION; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DIFFERENTIAL SCANNING CALORIMETRY; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG RELEASE; DRUG RESPONSE; DRUG STABILITY; DRUG UPTAKE; ENDOCYTOSIS; EXCIPIENT COMPATIBILITY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALIGNANT NEOPLASTIC DISEASE; MOUSE; NONHUMAN; OSMOTIC PRESSURE; PH MEASUREMENT; WIDE ANGLE X RAY DIFFRACTION; X RAY DIFFRACTION; ZETA POTENTIAL; ANIMAL; CHEMISTRY; GREEN CHEMISTRY; MEDICINAL CHEMISTRY; MICELLE; NANOMEDICINE; PROCEDURES; SUSPENSION; TUMOR CELL LINE;

ALBUMIN-BOUND PACLITAXEL; ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CHEMISTRY, PHARMACEUTICAL; GREEN CHEMISTRY TECHNOLOGY; HUMANS; MICE; MICELLES; NANOMEDICINE; POLYETHYLENE GLYCOLS; SUSPENSIONS;

EID: 84949975722     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S92697     Document Type: Article

References (52)

1. Jose Merlin JP, Venkadesh B, Hussain R, et al. Paclitaxel loaded poly-d, l-lactide-co-glycolide nanoparticles: enhanced anticancer effect in non-small cell lung carcinoma cell line. Biomed Prevent Nutr. 2013;3(1):1–9.
2. Tao Y, Han J, Wang X, Dou H. Nano-formulation of paclitaxel by vitamin E succinate functionalized pluronic micelles for enhanced encapsulation, stability and cytotoxicity. Colloid Surf B Biointerfaces. 2013;102:604–610.
3. Xin H, Chen L, Gu J, et al. Enhanced anti-glioblastoma efficacy by PTX-loaded PEGylated poly(ε-caprolactone) nanoparticles: in vitro and in vivo evaluation. Int J Pharm. 2010;402(1–2):238–247.
4. Sun Y, Yu B, Wang G, et al. Enhanced antitumor efficacy of vitamin E TPGS-emulsified PLGA nanoparticles for delivery of paclitaxel. Colloid Surf B Biointerfaces. 2014;123:716–723.
5. Sharma S, Verma A, Teja BV, Shukla P, Mishra PR. Development of stabilized Paclitaxel nanocrystals: In-vitro and in-vivo efficacy studies. Eur J Pharm Sci. 2015;69:51–60.
6. Pawar AP, Vinugala D, Bothiraja C. Nanocochleates derived from nanoliposomes for paclitaxel oral use: preparation, characterization, in vitro anticancer testing, bioavailability and biodistribution study in rats. Biomed Pharmacother. 2014;3502:1–9.
7. Yan F, Li L, Deng Z, et al. Paclitaxel-liposome-microbubble complexes as ultrasound-triggered therapeutic drug delivery carriers. J Control Release. 2013;166(3):246–255.
8. Lundberg BB, Risovic V, Ramaswamy M, Wasan KM. A lipophilic paclitaxel derivative incorporated in a lipid emulsion for parenteral administration. J Controll Release. 2003;86(1):93–100.
9. Rapoport N, Gupta R, Kim YS, O’Neill BE. Polymeric micelles and nanoemulsions as tumor-targeted drug carriers: insight through intravital imaging. J Control Release. 2015;206:153–160.
10. Bouquet W, Ceelen W, Fritzinger B, et al. Paclitaxel/beta-cyclodextrin complexes for hyperthermic peritoneal perfusion – formulation and stability. Eur J Pharm Biopharm. 2007;66(3):391–397.
11. Chun C, Lee SM, Kim SY, Yang HK, Song SC. Thermosensitive poly(organophosphazene)-paclitaxel conjugate gels for antitumor applications. Biomaterials. 2009;30(12):2349–2360.
12. Gao L, Liu G, Kang J, et al. Paclitaxel nanosuspensions coated with P-gp inhibitory surfactants: I. Acute toxicity and pharmacokinetics studies. Colloids Surf B Biointerfaces. 2013;111:277–281.
13. Schleich N, Sibret P, Danhier P, et al. Dual anticancer drug/superparamagnetic iron oxide-loaded PLGA-based nanoparticles for cancer therapy and magnetic resonance imaging. Int J Pharm. 2013;447(1–2):94–101.
14. Chin WW, Parmentier J, Widzinski M, Tan EH, Gokhale R. A brief literature and patent review of nanosuspensions to a final drug product. J Pharm Sci. 2014;103(10):2980–2999.
15. Langer K, Anhorn MG, Steinhauser I, et al. Human serum albumin (HSA) nanoparticles: reproducibility of preparation process and kinetics of enzymatic degradation. Int J Pharm. 2008;347(1–2):109–117.
16. Ranjbar S, Shokoohinia Y, Ghobadi S, et al. Studies of the interaction between isoimperatorin and human serum albumin by multispectroscopic method: identification of possible binding site of the compound using esterase activity of the protein. Scientific World J. 2013;2013:305081.
17. Chatpun S, Nacharaju P, Cabrales P. Improving cardiac function with new-generation plasma volume expanders. Am J Emerg Med. 2013;31(1):54–63.
18. Son S, Song S, Lee SJ, et al. Self-crosslinked human serum albumin nanocarriers for systemic delivery of polymerized siRNA to tumors. Biomaterials. 2013;34(37):9475–9485.
19. Li C, Li Y, Gao Y, et al. Direct comparison of two albumin-based paclitaxel-loaded nanoparticle formulations: is the crosslinked version more advantageous? Int J Pharm. 2014;468(1–2):15–25.
20. Ibrahim N, Ibrahim H, Dormoi J, et al. Albumin-bound nanoparticles of practically water-insoluble antimalarial lead greatly enhance its efficacy. Int J Pharm. 2014;464(1–2):214–224.
21. Crisante F, Francolini I, Bellusci M, Martinelli A, D’Ilario L, Piozzi A. Antibiotic delivery polyurethanes containing albumin and polyallylamine nanoparticles. Eur J Pharm Sci. 2009;36(4–5):555–564.
22. Yu S, Yao P, Jiang M, Zhang G. Nanogels prepared by self-assembly of oppositely charged globular proteins. Biopolymers. 2006;83(2):148–158.
23. Langer K, Balthasar S, Vogel V, Dinauer N, von Briesen H, Schubert D. Optimization of the preparation process for human serum albumin (HSA) nanoparticles. Int J Pharm. 2003;257(1–2):169–180.
24. Elzoghby AO, Samy WM, Elgindy NA. Albumin-based nanoparticles as potential controlled release drug delivery systems. J Control Release. 2012;157(2):168–182.
25. Lluch A, Alvarez I, Munoz M, Segui MA, Tusquets I, Garcia-Estevez L. Treatment innovations for metastatic breast cancer: nanoparticle albumin-bound (NAB) technology targeted to tumors. Crit Rev Oncol Hematol. 2014;89(1):62–72.
26. Gradishar WJ. Albumin-bound paclitaxel: a next-generation taxane. Expert Opin Pharmacother. 2006;7(8):1041–1053.
27. Catauro M, Bollino F, Papale F, Gallicchio M, Pacifico S. Influence of the polymer amount on bioactivity and biocompatibility of SiO2/PEG hybrid materials synthesized by sol-gel technique. Mat Sci Eng C Mater Biol Appl. 2015;48:548–555.
28. Qiu L, Zheng C, Jin Y, Zhu K. Polymeric micelles as nanocarriers for drug delivery. Expert Opin Ther Patents. 2007;17(7):819–830.
29. Danhier F, Lecouturier N, Vroman B, et al. Paclitaxel-loaded PEGylated PLGA-based nanoparticles: in vitro and in vivo evaluation. J Control Release. 2009;133(1):11–17.
30. Cui F, Li Y, Zhou S, et al. A comparative in vitro evaluation of self-assembled PTX-PLA and PTX-MPEG-PLA nanoparticles. Nanoscale Res Lett. 2013;8(1):301–308.
31. Hahnenkamp A, Alsibai W, Bremer C, Holtke C. Optimizing the bioavailability of small molecular optical imaging probes by conjugation to an albumin affinity tag. J Control Release. 2014;186:32–40.
32. Zhong Y, Yang W, Sun H, et al. Ligand-directed reduction-sensitive shell-sheddable biodegradable micelles actively deliver doxorubicin into the nuclei of target cancer cells. Biomacromolecules. 2013;14(10):3723–3730.
33. Xie J, Chen K, Huang J, et al. PET/NIRF/MRI triple functional iron oxide nanoparticles. Biomaterials. 2010;31(11):3016–3022.
34. Wang H, Sun X, Gao F, Zhong B, Zhang YH, Sun Z. Effect of ulinastatin on growth inhibition, apoptosis of breast carcinoma cells is related to a decrease in signal conduction of JNk-2 and NF-kappaB. J Exp Clin Cancer Res. 2012;31:1–13.
35. Pelzer ES, Harris JE, Allan JA, et al. TUNEL analysis of DNA fragmentation in mouse unfertilized oocytes: the effect of microorganisms within human follicular fluid collected during IVF cycles. J Reprod Immunol. 2013;99(1–2):69–79.
36. Wu D, Zheng Y, Hu X, Fan Z, Jing X. Anti-tumor activity of folate targeted biodegradable polymer-paclitaxel conjugate micelles on EMT-6 breast cancer model. Mater Sci Eng C Mater Biol Appl. 2015;53:68–75.
37. Dang Y, Zhu C. Genomic study of the absorption mechanism of cantharidin and its solid dispersion. Colloid Surf A Physicochem Eng Asp. 2012;415:295–301.
38. Liu X, Lu M, Guo Z, Huang L, Feng X, Wu C. Improving the chemical stability of amorphous solid dispersion with cocrystal technique by hot melt extrusion. Pharm Res. 2012;29(3):806–817.
39. Lima AA, Soares-Sobrinho JL, Silva JL, et al. The use of solid dispersion systems in hydrophilic carriers to increase benzonidazole solubility. J Pharm Sci. 2011;100(6):2443–2451.
40. Bekale L, Agudelo D, Tajmir-Riahi HA. The role of polymer size and hydrophobic end-group in PEG-protein interaction. Colloid Surf B Biointerfaces. 2015;130:141–148.
41. Yadav SK, Mishra S, Mishra B. Eudragit-based nanosuspension of poorly water-soluble drug: formulation and in vitro-in vivo evaluation. AAPS Pharm Sci Tech. 2012;13(4):1031–1044.
42. Guo S, Huang L. Nanoparticles escaping RES and endosome: challenges for siRNA delivery for cancer therapy. J Nanomater. 2011;2011:11.
43. Maeda H, Bharate GY, Daruwalla J. Polymeric drugs for efficient tumor-targeted drug delivery based on EPR-effect. Eur J Pharm Biopharm. 2009;71(3):409–419.
44. Wu L, Zhang J, Watanabe W. Physical and chemical stability of drug nanoparticles. Adv Drug Deliv Rev. 2011;63(6):456–469.
45. Huo M, Zhang Y, Zhou J, et al. Synthesis and characterization of low-toxic amphiphilic chitosan derivatives and their application as micelle carrier for antitumor drug. Int J Pharm. 2010;394(1–2):162–173.
46. Frei E. Albumin binding ligands and albumin conjugate uptake by cancer cells. Diabetol Metab Syndr. 2011;3(1):11.
47. Gao L, Liu G, Ma J, et al. Paclitaxel nanosuspension coated with P-gp inhibitory surfactants: II. Ability to reverse the drug-resistance of H460 human lung cancer cells. Colloid Surf B Biointerfaces. 2014;117:122–127.
48. Fang J, Liao L, Yin H, Nakamura H, Shin T, Maeda H. Enhanced bacterial tumor delivery by modulating the EPR effect and therapeutic potential of Lactobacillus casei. J Pharm Sci. 2014;103(10):3235–3243.
49. Lu J, Huang Y, Zhao W, et al. Design and characterization of PEG-derivatized vitamin E as a nanomicellar formulation for delivery of paclitaxel. Mol Pharm. 2013;10(8):2880–2890.
50. Gligorov J, Lotz JP. Preclinical pharmacology of the taxanes: implications of the differences. Oncologist. 2004;9(Suppl 2):3–8.
51. Gong J, Huo M, Zhou J, et al. Synthesis, characterization, drug-loading capacity and safety of novel octyl modified serum albumin micelles. Int J Pharm. 2009;376(1–2):161–168.
52. ten Tije AJ, Verweij J, Loos WJ. Sparreboom A. Pharmacological effects of formulation vehicles: implications for cancer chemotherapy. Clin Pharmacokinet. 2003;42(7):665–685